Therefore, the impact of a congenital FXI deficiency on bleeding tendencies and treatment of individuals with thrombotic disorders with inhibitors of FXIa or FXIIa should be further investigated to better understand the impact on hemostasis and the potential bleeding risk associated with such interventions. Here, F11 is linked to thrombotic disease.